Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b, safety, PK, and efficacy, multicenter, dose-escalating study of imprime PGG in combination with cetuximab/irinotecan therapy in patients with and without recurrent/progressive colorectal carcinoma following treatment with a 5-FU regimen

Next Previous
X
Search
Trial Profile

A phase 1b, safety, PK, and efficacy, multicenter, dose-escalating study of imprime PGG in combination with cetuximab/irinotecan therapy in patients with and without recurrent/progressive colorectal carcinoma following treatment with a 5-FU regimen

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odetiglucan (Primary) ; Cetuximab; Irinotecan
  • Indications Carcinoma; Colorectal cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors Biothera

    • Most Recent Events

    • 13 Oct 2010 Final results have been presented at the 35th European Society for Medical Oncology (ESMO) Congress, according to a Biothera media release. Results from both study arms, plus a retrospective analysis, were also reported in the media release.
    • 07 Jul 2010 Results presented at the World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology and also in media release from Biothera.
    • 02 Apr 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top